Baricitinib in rheumatoid arthritis-associated interstitial lung disease: a national multicenter study of 84 patients (ACR Convergence 2026) - Sep 8, 2026 - Abstract #478; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Abatacept and rituximab are currently recommended therapies...JAKi approved by the FDA and EMA for RA treatment include tofacitinib, baricitinib, upadacitinib, and filgotinib...Median prednisone dose was reduced from 5 mg/day to 0 mg/day. Baricitinib may represent an effective and safe therapeutic alternative for controlling both pulmonary and articular manifestations in patients with RA-ILD, including refractory cases."
Clinical • Cardiovascular • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology
|
|
Laura Muñoz1; Ana Serrano-Combarro1; Belén Atienza-Mateo1; César Antonio Egües Dubuc2; Nuria Vegas Revenga3; Ignacio Braña Abascal4; Deseada Palma Sánchez5; Jesús Loarce Martos6; Marta Pastor Mena7; Sara María Rojas Herrera8; Andrea García Valle9; Carmen Carrasco Cubero10; Ivette Casafont-Sole11; Juan María Blanco Madrigal12; María López Lasanta13; MARIA MARTIN14; Virginia Ruiz-Esquide15; Carolina Pérez García16; María Paz Martínez-Vidal17; David Castro-Corredor18; Evelin Cecilia Cervantes Pérez19; José Ramón Lamúa Riazuelo20; Lorena Pérez Albaladejo21; Marta Garijo Bufort22; Natalia Mena-Vázquez23; Rafael B. Melero-González24; Rafaela Ortega-Castro25; Uxue Astigarraga Urquia26; Gema Bonilla27; Santos Castañeda28; Ricardo Blanco29
|